Paya N’Diaye, Guangxun Meng, Nathalie Aulner, Eric Prina, Hugo Varet, Kossiwa Kokou, Robert Weil, Yue Xing, Thibault Rosazza, Gerald F. Späth, Geneviève Milon, Giovanni Bussotti, Hervé Lecoeur, Parasitologie moléculaire et Signalisation / Molecular Parasitology and Signaling, Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Key Laboratory of Molecular Virology and Immunology [Shanghai, China], Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), BioImagerie Photonique – Photonic BioImaging (UTechS PBI), Institut Pasteur [Paris], Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), This project was supported by a fund of the Institut Pasteur International Direction to the International Mixed Unit 'Inflammation and Leishmania Infection' and by the International Partnership Program (153831KYSB20190008) of the Chinese Academy of Sciences. The UtechS PBI/C2RT is part of the FranceBioImaging infrastructure, supported by the French National Research Agency (ANR-10-INSB-04-01, Investments for the Future) and is supported by Conseil de la Région Ile-de-France (Domaine d’Intérêt Majeur DIM1HEALTH) and Fondation Française pour la Recherche Médicale (Programme Grands Equipements)., ANR-10-INBS-0004,France-BioImaging,Développment d'une infrastructure française distribuée coordonnée(2010), Parasitologie moléculaire et Signalisation, Key Laboratory of Molecular Virology & Immunology (LMVI), Pasteur International Mixed Unit 'Inflammation and Leishmania infection' (IMU-InflaLeish), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Innate Immunity [China], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur de Shanghai, Académie des Sciences de Chine - Chinese Academy of Sciences (IPS-CAS), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Leishmania Lab [Corée du sud], Institut Pasteur de Corée, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut Pasteur de Corée, Réseau International des Instituts Pasteur (RIIP), Technologie et Service BioImagerie Photonique – Photonic BioImaging (UTechS PBI), Centre de Ressources et de Recherche Technologique - Center for Technological Resources and Research (C2RT), Institut Pasteur [Paris]-Institut Pasteur [Paris], This project was supported by a fund of the Institut Pasteur International Direction to the International Mixed Unit 'Inflammation and Leishmania Infection' and by the International Partnership Program (153831KYSB20190008) of the Chinese Academy of Sciences. We would like to thank Jean-Marc Cavaillon for support and helpful discussions and Drs. Emmanuel Laplantine and Anastassia V. Komarova for providing antibodies. The UtechS PBI/C2RT is part of the FranceBioImaging infrastructure, supported by the French National Research Agency (ANR-10-INSB-04-01, Investments for the Future) and is supported by Conseil de la Région Ile-de-France (Domaine d’Intérêt Majeur DIM1HEALTH) and Fondation Française pour la Recherche Médicale (Programme Grands Equipements)., ANR-10-INSB-04-01,INSB,Investissements d'Avenir, Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Varet, Hugo, and Développment d'une infrastructure française distribuée coordonnée - - France-BioImaging2010 - ANR-10-INBS-0004 - INBS - VALID
Summary: Aberrant macrophage activation during intracellular infection generates immunopathologies that can cause severe human morbidity. A better understanding of immune subversion strategies and macrophage phenotypic and functional responses is necessary to design host-directed intervention strategies. Here, we uncover a fine-tuned transcriptional response that is induced in primary and lesional macrophages infected by the parasite Leishmania amazonensis and dampens NF-κB and NLRP3 inflammasome activation. Subversion is amastigote-specific and characterized by a decreased expression of activating and increased expression of de-activating components of these pro-inflammatory pathways, thus revealing a regulatory dichotomy that abrogates the anti-microbial response. Changes in transcript abundance correlate with histone H3K9/14 hypoacetylation and H3K4 hypo-trimethylation in infected primary and lesional macrophages at promoters of NF-κB-related, pro-inflammatory genes. Our results reveal a Leishmania immune subversion strategy targeting host cell epigenetic regulation to establish conditions beneficial for parasite survival and open avenues for host-directed, anti-microbial drug discovery. : Lecoeur et al. demonstrate that the parasite Leishmania amazonensis modifies expression of NF-kB-related genes and prevents NLRP3 inflammasome activation of host macrophages in vitro and in vivo by changing histone H3 modifications at the promotor of pro-inflammatory genes. This mechanism of immune subversion opens avenues for host-directed, anti-leishmanial therapies. Keywords: Leishmania amazonensis, amastigotes, lesional macrophage, NF-κB, NLRP3 inflammasome, H3 acetylation, H3 methylation, epigenetics, histone